← Leaderboards
Sanjay Jain
Johns Hopkins University
$27,871,118
Attributed
$33,249,052
Total exposure
18
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,249,052 · 18
By mechanism
R01$23,665,023 · 9
DP2$2,941,111 · 1
T32$2,006,973 · 1
S10$1,695,141 · 1
R56$1,656,680 · 2
R21$895,813 · 2
Top collaborators
- David M Wilson7 shared
- Tejal A. Desai3 shared
- Robert Richard Flavell3 shared
- Alvaro Andres Ordonez2 shared
- Anne Hamacher-Brady1 shared
- Petros C Karakousis1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Martin G Pomper$38,517,075
- Barbara Stauch Slusher$18,499,514
- Kannan Rangaramanujam$10,355,612
- Vernon Bruce Carruthers$18,903,624
- Elizabeth A Eipper$13,280,286
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionImagePositron-Emission TomographyMycobacterium TuberculosisTissuesLungPharmaceutical PreparationsAnimalsBaseLesionTracerTechnologyInflammationSiteDoseDrug KineticsRegimenImaging DeviceAnimal ModelPenetrationPathogenRifampinInsightAntimicrobial
Grant awards (49)
Advancing Apoptosis-Inducing Agents as Host-Directed Therapy for TB$2,922,220
R01 · FY2025 · AI
Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis$774,881
R01 · FY2025 · AI · contact PI
PET to Assess Post-TB Lung Disease in TB Patients with / without HIV coinfection$445,500
R21 · FY2025 · AI · contact PI
Research Training in Pediatric Infectious Diseases$397,203
T32 · FY2025 · AI · contact PI
Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis$817,941
R56 · FY2024 · AI · contact PI
Preclinical modeling to study Tuberculous Meningitis$782,304
R01 · FY2024 · AI · contact PI
Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging$768,371
R01 · FY2024 · AI · contact PI
Research Training in Pediatric Infectious Diseases$362,691
T32 · FY2024 · AI · contact PI
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$805,361
R01 · FY2023 · AI
Preclinical modeling to study Tuberculous Meningitis$786,130
R01 · FY2023 · AI · contact PI
Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging$777,071
R01 · FY2023 · AI · contact PI
Research Training in Pediatric Infectious Diseases$346,493
T32 · FY2023 · AI · contact PI
7T Cryogen-Free Preclinical MRI for small animals to study infectious diseases in BSL-3 containment$1,695,141
S10 · FY2022 · OD · contact PI
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$809,270
R01 · FY2022 · AI
Preclinical modeling to study Tuberculous Meningitis$793,509
R01 · FY2022 · AI · contact PI
Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging$735,031
R01 · FY2022 · AI · contact PI
Research Training in Pediatric Infectious Diseases$302,921
T32 · FY2022 · AI · contact PI
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$828,473
R01 · FY2021 · AI
Preclinical modeling to study Tuberculous Meningitis$810,795
R01 · FY2021 · AI · contact PI
Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging$744,062
R01 · FY2021 · AI · contact PI
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections$691,499
R01 · FY2021 · EB
Research Training in Pediatric Infectious Diseases$292,654
T32 · FY2021 · AI · contact PI
Measuring Intralesional Bedaquiline Exposures in Cavitary TB Using Noninvasive In Vivo PET Imaging$204,688
R21 · FY2021 · AI · contact PI
Preclinical modeling to study Tuberculous Meningitis$836,718
R01 · FY2020 · AI · contact PI
Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging$816,236
R01 · FY2020 · AI · contact PI
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections$719,894
R01 · FY2020 · EB
Research Training in Pediatric Infectious Diseases$305,011
T32 · FY2020 · AI · contact PI
Measuring Intralesional Bedaquiline Exposures in Cavitary TB Using Noninvasive In Vivo PET Imaging$245,625
R21 · FY2020 · AI · contact PI
Preclinical modeling to study Tuberculous Meningitis$838,739
R56 · FY2019 · AI · contact PI
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections$658,515
R01 · FY2019 · EB
Molecular Imaging for Pulmonary Infections and Inflammation$705,653
R01 · FY2018 · HL · contact PI
Novel Imaging Tracers for Rapid and Noninvasive Assessment of Bacterial Infection$698,542
R01 · FY2018 · EB · contact PI
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections$674,697
R01 · FY2018 · EB
Molecular Imaging for Pulmonary Infections and Inflammation$720,392
R01 · FY2017 · HL · contact PI
Novel Imaging Tracers for Rapid and Noninvasive Assessment of Bacterial Infection$712,734
R01 · FY2017 · EB · contact PI
Molecular Imaging for Pulmonary Infections and Inflammation$733,500
R01 · FY2016 · HL · contact PI
Novel Imaging Tracers for Rapid and Noninvasive Assessment of Bacterial Infection$715,620
R01 · FY2016 · EB · contact PI
Enhancing Health Care Access with Cellular Technology$127,646
R03 · FY2016 · EB · contact PI
Novel Imaging Tracers for Rapid and Noninvasive Assessment of Bacterial Infection$25,000
R01 · FY2016 · EB · contact PI
Novel Imaging Tracers for Rapid and Noninvasive Assessment of Bacterial Infection$714,358
R01 · FY2015 · EB · contact PI
Enhancing Health Care Access with Cellular Technology$128,693
R03 · FY2015 · EB · contact PI
Novel Imaging Tracers for Rapid and Noninvasive Assessment of Bacterial Infection$716,727
R01 · FY2014 · EB · contact PI
Novel imaging biomarkers to address fundamental controversies in TB pathogenesis$481,111
DP2 · FY2014 · OD · contact PI
Molecular Imaging for Macrophage-Associated Pulmonary Inflammation$396,900
R01 · FY2014 · HL · contact PI
Molecular Imaging for Macrophage-Associated Pulmonary Inflammation$385,560
R01 · FY2013 · HL · contact PI
Molecular Imaging for Macrophage-Associated Pulmonary Inflammation$405,000
R01 · FY2012 · HL · contact PI
Diagnosis of active TB in HIV infected and uninfected young children in India$65,636
R03 · FY2010 · HD · contact PI
Novel imaging biomarkers to address fundamental controversies in TB pathogenesis$2,460,000
DP2 · FY2009 · OD · contact PI
Diagnosis of active TB in HIV infected and uninfected young children in India$66,336
R03 · FY2009 · HD · contact PI